Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Day One Biopharmaceuticals Inc (DAWN)

Day One Biopharmaceuticals Inc (DAWN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,343,602
  • Shares Outstanding, K 73,461
  • Annual Sales, $ 0 K
  • Annual Income, $ -70,650 K
  • 60-Month Beta -3.69
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.33
Trade DAWN with:

Options Overview Details

View History
  • Implied Volatility 111.60% ( -13.47%)
  • Historical Volatility 55.89%
  • IV Percentile 46%
  • IV Rank 27.76%
  • IV High 259.71% on 06/10/22
  • IV Low 54.68% on 03/24/22
  • Put/Call Vol Ratio 1.37
  • Today's Volume 71
  • Volume Avg (30-Day) 118
  • Put/Call OI Ratio 1.96
  • Today's Open Interest 3,857
  • Open Int (30-Day) 3,991

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.53
  • Number of Estimates 4
  • High Estimate -0.45
  • Low Estimate -0.63
  • Prior Year -0.33
  • Growth Rate Est. (year over year) -60.61%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.02 +7.44%
on 09/23/22
26.72 -31.55%
on 09/12/22
-6.21 (-25.35%)
since 08/23/22
3-Month
16.00 +14.31%
on 08/02/22
28.35 -35.48%
on 08/12/22
+0.84 (+4.81%)
since 06/23/22
52-Week
5.44 +236.21%
on 05/27/22
28.35 -35.48%
on 08/12/22
-6.05 (-24.86%)
since 09/23/21

Most Recent Stories

More News
Foundation Medicine and Day One Biopharmaceuticals Announce Global Collaboration to Advance Pediatric Cancer Care

Foundation Medicine, Inc. , a pioneer in molecular profiling for cancer, and Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...

DAWN : 18.29 (+3.10%)
Here's What Could Help Day One Biopharmaceuticals, Inc. (DAWN) Maintain Its Recent Price Strength

Day One Biopharmaceuticals, Inc. (DAWN) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move....

DAWN : 18.29 (+3.10%)
Day One Reports Second Quarter 2022 Financial Results and Corporate Progress

Reported positive initial data from ongoing pivotal FIREFLY-1 study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG); topline...

DAWN : 18.29 (+3.10%)
Day One to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company...

DAWN : 18.29 (+3.10%)
Wall Street Analysts Think Day One Biopharmaceuticals, Inc. (DAWN) Could Surge 85%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 84.6% in Day One Biopharmaceuticals, Inc. (DAWN). While the effectiveness of this highly sought-after metric is...

DAWN : 18.29 (+3.10%)
Insiders Invested More Than $40 Million in This Stock with Major Upside Potential

Clinical-stage biopharmaceuticals company Day One Biopharmaceuticals (DAWN) is still in its early stages of development and has yet to generate revenue. However, recent insider buying activity in the stock...

DAWN : 18.29 (+3.10%)
Biotech ETF Tops in June: 5 Stocks That Outperform

Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' bargain...

MRTX : 68.18 (-2.52%)
BBC : 23.07 (-2.96%)
KZR : 8.02 (+0.12%)
RPTX : 12.00 (+3.00%)
DAWN : 18.29 (+3.10%)
LYEL : 6.38 (-5.62%)
Insiders Go All-In on These 2 ‘Strong Buy’ Stocks

Downturns can bring a lot of pain, but they can also bring on plenty of opportunities, as lower stock prices start making costs of entry more attractive. Before taking advantage of these opportunities,...

HRT : 15.20 (-2.56%)
DAWN : 18.29 (+3.10%)
Day One Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical...

DAWN : 18.29 (+3.10%)
Here's How Day One Biopharmaceuticals Stock Could Keep Climbing

A giant run-up on Monday could be the beginning of a much larger bull run.

COMP : 2.35 (+2.62%)
DAWN : 18.29 (+3.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Day One Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Day One Biopharmaceuticals Inc. is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 20.05
2nd Resistance Point 19.19
1st Resistance Point 18.74
Last Price 18.29
1st Support Level 17.43
2nd Support Level 16.57
3rd Support Level 16.12

See More

52-Week High 28.35
Fibonacci 61.8% 19.60
Last Price 18.29
Fibonacci 50% 16.89
Fibonacci 38.2% 14.19
52-Week Low 5.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar